Previous close | 0.7000 |
Open | 0.2000 |
Bid | 0.0500 |
Ask | 0.1500 |
Strike | 5.00 |
Expiry date | 2024-05-17 |
Day's range | 0.1000 - 0.2500 |
Contract range | N/A |
Volume | |
Open interest | 788 |
Monday, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a first-quarter earnings loss of $(0.17) per share versus the consensus estimate loss of $(0.21) per share and $(0.28) reported a year ago. BioCryst Pharma reported sales of $92.8 million, beating the consensus of $85.61 million. The sales increased 34.9% Y/Y, primarily due to $88.9 million in Orladeyo’s net revenue in the first quarter of 2024, up 30% Y/Y. “We are off to a fantastic start to the year with outstanding Orladeyo revenue g
Significant Growth in ORLADEYO Sales and Strategic Pipeline Advancements Mark the Quarter
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?